Livongo health, inc. (LVGO)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss

-5,573

-6,354

-19,712

-14,833

-14,371

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense

1,200

1,026

800

800

700

Amortization of intangible assets

696

696

696

629

564

Non-cash operating lease cost

1,100

-

-

-

-

Change in fair value of contingent consideration

84

-168

55

282

674

Allowance for doubtful accounts

235

353

-10

413

98

Stock-based compensation expense

8,063

6,905

15,580

4,637

5,510

Deferred income taxes

0

-

0

0

-1,396

Changes in operating assets and liabilities, net of impact of acquisitions:
Accounts receivable, net

11,806

328

5,804

5,721

11,916

Inventories

-9,738

7,709

7,439

5,373

-472

Deferred costs

11,196

271

893

1,937

5,510

Prepaid expenses and other assets

764

424

4,379

-2,936

2,609

Accounts payable

-98

945

-1,216

-885

3,142

Accrued expenses and other liabilities

-3,024

1,464

5,789

1,238

-480

Operating lease liabilities

-546

-

-

-

-

Deferred revenue

1,500

14

475

578

75

Advance payments from partner

0

0

424

2,508

-136

Net cash used in operating activities

-10,400

-3,867

-15,572

-14,761

-25,200

CASH FLOWS FROM INVESTING ACTIVITIES
Purchases of property and equipment

1,762

661

706

288

340

Capitalized internal-use software costs

1,325

1,641

1,180

1,094

1,284

Acquisitions, net of cash acquired

0

0

0

0

27,435

Net cash used in investing activities

-3,087

-100,986

-51,886

-948

-29,059

CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from exercise of stock options, net of repurchases

1,722

1,137

516

1,129

314

Payment of deferred offering costs

286

-

-

1,559

0

Payment of deferred acquisition-related contingent consideration

884

3,732

0

0

0

Taxes paid related to net share settlement of equity awards

10,564

-

-

-

0

Net cash (used in) provided by financing activities

-10,012

-3,233

379,525

-430

314

Net decrease in cash, cash equivalents, and restricted cash

-23,510

-108,082

312,067

-16,152

-53,932

SUPPLEMENTAL DISCLOSURES OF NONCASH INVESTING AND FINANCING ACTIVITIES:
Accretion of redeemable convertible preferred stock

0

0

13

42

41

Purchases of property and equipment included in accounts payable and accrued liabilities

491

-203

276

-25

112

Contingent consideration liability

0

-

-

-

3,300

Unpaid working capital adjustment related to myStrength acquisition

0

-

-

-

119

Capitalized internal-use software costs in accounts payable and accrued liabilities

-141

106

-34

102

-163

Common Stock
Unpaid offering costs

0

-

-1,117

981

331